title: [FRα: a target for prophylactic photodynamic therapy of ovarian peritoneal metastasis?].
abstract: Partly due to delays in its diagnosis, ovarian cancer's prognosis remains dire after primary therapy. Treatment consists in complete cytoreductive surgery and platinum-based chemotherapy. Recurrence rates are disappointingly high, as 60% of women with advanced epithelial ovarian cancer considered in remission will develop recurrent disease within five years. Special attention to undetected peritoneal metastasis and residual tumorous cells during surgery is necessary as they are the main predictors of recurrences. Targeted therapies aim to bring chemotherapy, radiotherapy and selective tumor photosensitizer (PS) agents to the targeted cell and its tumoral microenvironment. Folate receptor α (FRα) shows promising prospects in targeting ovarian cancerous cells. Indeed, with good specificity and frequent overexpression in ovarian cancer, FRα is a recurrent topic in recent publications. The aim of this review is to present FRα and the reasons that make it an ideal targeting ligand for ovarian carcinoma therapy. Prophylactic photodynamic therapy (PPDT) using new generation FRα-coupled agents combined with complete cytoreductive surgery could allow for a significant decrease in recurrence rates. Preclinical trials are being run in order to allow for human clinical applications.
authors.affiliation: CHRU de Lille, Unité Inserm U703, 152, rue du Dr-Yersin, 59120 Loos, France, CHRU de Lille, Hôpital Jeanne de Flandre, Service de gynécologie, 59000 Lille, France.
authors.forename: Henri
authors.initials: H
authors.lastname: Azaïs
authors.affiliation: Université de Lorraine, UMR 7274 CNRS, Laboratoire réactions et génie des procédés, 54000 Nancy, France.
authors.forename: Albert
authors.initials: A
authors.lastname: Moussaron
authors.affiliation: CHRU de Lille, Unité Inserm U703, 152, rue du Dr-Yersin, 59120 Loos, France, CHRU de Lille, Hôpital Jeanne de Flandre, Service de gynécologie, 59000 Lille, France.
authors.forename: Soraya
authors.initials: S
authors.lastname: Khodja Bach
authors.affiliation: CHRU de Lille, Unité Inserm U703, 152, rue du Dr-Yersin, 59120 Loos, France, CHRU de Lille, Hôpital Jeanne de Flandre, Service de gynécologie, 59000 Lille, France.
authors.forename: Alfred
authors.initials: A
authors.lastname: Bassil
authors.affiliation: CHRU de Lille, Unité Inserm U703, 152, rue du Dr-Yersin, 59120 Loos, France.
authors.forename: Nacim
authors.initials: N
authors.lastname: Betrouni
authors.affiliation: Université de Lorraine, UMR 7274 CNRS, Laboratoire réactions et génie des procédés, 54000 Nancy, France.
authors.forename: Céline
authors.initials: C
authors.lastname: Frochot
authors.affiliation: CHRU de Lille, Unité Inserm U703, 152, rue du Dr-Yersin, 59120 Loos, France, CHRU de Lille, Hôpital Jeanne de Flandre, Service de gynécologie, 59000 Lille, France.
authors.forename: Pierre
authors.initials: P
authors.lastname: Collinet
authors.affiliation: CHRU de Lille, Unité Inserm U703, 152, rue du Dr-Yersin, 59120 Loos, France.
authors.forename: Serge
authors.initials: S
authors.lastname: Mordon
mesh_terms: D004338:Drug Combinations; D005260:Female; D058975:Folate Receptor 1; D005492:Folic Acid / Q000737:chemistry / Q000627:therapeutic use*; D006801:Humans; D058990:Molecular Targeted Therapy / Q000379:methods; D010051:Ovarian Neoplasms / Q000737:chemistry* / Q000473:pathology*; D010534:Peritoneal Neoplasms / Q000517:prevention & control* / Q000556:secondary*; D010778:Photochemotherapy / Q000379:methods*; D017319:Photosensitizing Agents / Q000737:chemistry / Q000627:therapeutic use*; D011166:Porphyrins / Q000737:chemistry / Q000627:therapeutic use*
chemical_list: D004338:Drug Combinations; D058975:Folate Receptor 1; D017319:Photosensitizing Agents; D011166:Porphyrins; C409084:tetraphenylporphyrin; D005492:Folic Acid
keywords: folate receptor α; ovarian cancer; peritoneal carcinomatosis; prophylactic photodynamic therapy; targeted therapy